Tech Company Financing Transactions
Terrestrial Bio Funding Round
On 3/26/2026, Terrestrial Bio raised $50 million in Series C funding from RA Capital, Engine Ventures and Global Health Investment Corporation.
Transaction Overview
Company Name
Announced On
3/26/2026
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Proceeds Purpose
With its new funding, the company has signed a lease with King Street Properties for a new manufacturing facility at Allston Labworks.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
127 Western Ave.
Boston, MA 02134
USA
Boston, MA 02134
USA
Phone
Website
Email Address
Not Recorded
Overview
Terrestrial Bio, Inc. (formerly Vaxess Technologies) is a clinical-stage biotechnology company focused on transforming the delivery of next-generation therapies. The company aims to make therapeutic delivery more patient-friendly and accessible by replacing traditional needles with its proprietary MIMIX� microarray patch (MAP) platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel Sha
Chief Technical Officer
Mark Tracy
Co-Founder
Fiorenzo Omenetto
VP - Bus. Development
Livio Valenti
VP - R & D
Jonathan Kluge
VP - R & D
Kathryn Kosuda
Browse more venture capital transactions:
Prev: 3/26/2026: Tazapay venture capital transaction
Next: 3/26/2026: Conntour venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs